Rilutek Articles

Amyotrophic lateral sclerosis sector lacks new and effective treatment options

6 February 2013

Poland’s pharma distribution seeing many changes, with significant consolidation among wholesalers

9 February 2010

Trophos initiates pivotal efficacy study of ALS drug

6 May 2009

Scientists discover why animal studies may lead to ineffective ALS drugs

28 January 2008

Trophos completes Ph Ib TRO19622 program

11 December 2006

Pyhtopharm presents quarterly update on pipeline developments

1 May 2006

New Zealand opposition slams Pharmac over sole supply, urges national Rx policy

18 April 2005

Impax comments on Rilutek generic ruling

6 September 2004

NICE guidance implementation in England/ Wales studied, shows mixed results

31 May 2004

ExonHit says ALS study is on track

24 February 2003

Impax gets US OK for generic Rilutek

3 February 2003

IMPAX gains another ANDA, for riluzole

29 July 2002

Massive hike in net income for Aventis in 2000 as focus is firmly placed on

2 March 2001

UK industry "very disappointed" as NICE confirms that it will make PADs

8 February 2001

NICE backs three AD, one ALS drug for England/Wales: end to postcode Rxing?

24 January 2001

NICE: no guidance on glatiramer and beta interferon in MS before February

12 December 2000

Rhone-Poulenc sales flat for third quarter

8 November 1999

R-P's net income plunges 82%

28 July 1999

Rhone-Poulenc's oncology products drive growth, doubts emerge over Aventis

6 May 1999

Rilutek trial in Parkinson's

11 February 1999

Strong sales growth for Rhone-Poulenc in the USA, merger with Hoechst on

4 February 1999

EMEA pledges EPAR revision, assessment report guidance document this year

13 January 1999

Aventis Pipeline Rich In Near-Term Prospects

10 December 1998

R-PR Begins Rilutek Trial In Parkinson's

25 November 1998

Rhone-Poulenc Net Income Rises 8% For 3rd Qtr

30 October 1998

Double-Digit Pharma Sales Growth Boosts Rhone-Poulenc

29 April 1998

High Hopes For New Products At Rhone-Poulenc

5 February 1998

Rhone-Poulenc 3rd Qtr Net Income Up 38.8%

31 October 1997

Cephalon Chief On FDA Panel Decision

26 May 1997

FDA Panel Rejects Myotrophin Again

19 May 1997

Israel: Updating The Drug Basket, Funding Innovation

10 February 1997

Record Number Of New Chemical Entities In 1996

20 January 1997

Product News In 1996 Dominated By CNS

23 December 1996

Further Approvals For R-PR's Rilutek

2 December 1996

The Health Products Industry And The Internet

18 November 1996

R-PR's 18% EPS Rise Drives Parent Co In 3rd Qtr

4 November 1996

R-PR Divulges R&D Pipeline Developments

23 September 1996

Cephalon Sticks To Myotrophin Plan

16 September 1996

R-PR Posts Profits Climb But Flat Turnover In First Half

5 August 1996

UK Launch For R-PR's Rilutek

5 August 1996

Myotrophin Approved For Compassionate Use In USA

17 June 1996

R-PR Receives EU Approval For Rilutek

17 June 1996

Rhone-Poulenc Rorer's "Year Of Firsts"

5 February 1996

Cephalon Setback No Cause For Alarm, Say Analysts

29 January 1996

New York Stock Comment

22 January 1996

First Launch Of Rilutek, R-PR's ALS Drug

15 January 1996

First Approved Therapy For ALS From R-PR

18 December 1995

No Drug Approval Lag, "At Least Not In The USA"

18 December 1995

R-PR Starts Fisons R&D Integration; Product Update

4 December 1995

Rilutek Backed For Approval In USA

25 September 1995

Prospects For Glutamate Antagonists In Stroke

18 September 1995

R-PR's Rilutek In Canada

17 July 1995

R-PR First Filings For Rilutek In ALS

10 July 1995

R-P Rorer given Investigational approval for Rilutek

3 July 1995

Cephalon's Myotrophin Clears Major Hurdle

19 June 1995

Phase III Riluzole Data Presented At AAN

22 May 1995

Phase III Riluzole Results in ALS Patients

10 April 1995

R-PR Looks To New Products For Growth

20 February 1995

EUROPEAN STOCK COMMENT

14 March 1994

R-PR'S RILUZOLE EFFECTIVE IN ALS

7 March 1994

Showing 1-60 of 60 articles

Go to beginningPrevious
  • 1
NextGo to end